Author

Muhammed Hamdi Uyar

Observed names: M. Uyar, Uyar, Muhammed Hamdi

Institution: Aksaray University

Observed institution: Aksaray University

ORCID: 0000-0002-6670-7717

Observed ORCID: 0000-0002-6670-7717

OpenAlex ID: A5083535779

High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center

2023 · Murat Bektaş, Servet Yüce, et al. · Inflammopharmacology · 7

Intravenous high-dose anakinra drops venous thrombosis and acute coronary syndrome in severe and critical COVID-19 patients: a propensity score matched study

2024 · Ramazan Çakmak, Servet Yüce, et al. · Scientific Reports · 3

Combination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: Promising results from retrospective observational study

2024 · Murat Bektaş, Mustafa Ay, et al. · International Immunopharmacology · 3

Ab0087 Intravenous High-dose Anakinra Drops Venous Thrombosis and Myocardial Infarction in Severe and Critical Covid-19 Patients: a Propensity Score Matched Study

2024 · M. Bektaş, M. Ay, et al. · Annals of the Rheumatic Diseases

Intravenous High-dose Anakinra Drops Venous Thrombosis and Myocardial Infarction in Severe and Critical COVID-19 Patients: A Propensity Score Matched Study

2023 · Murat Bektas, Ramazan Çakmak, et al.

Pos0555 High Dose Intravenous Anakinra Treatment Is Safe and Effective in Severe and Critical Covid-19 Patients: a Propensity Score Matched Study in a Single Center

2023 · M. Bektaş, S. Yüce, et al. · Annals of the Rheumatic Diseases

Individualized High Dose Intravenous Anakinra Treatment is Safe and Effective in Patients with COVID-19 Associated Cytokine Storm Accompanying Cancer: A Retrospective Matched Study

2022 · Murat Bektaş, Murat Bektaş, et al.

Works count: 8

Citation count: 13

H-index: 3

I10-index: